1. Clinical & Scientific Overview
Clopidogrel Bisulfate (TIP-MED-000019, Reference Code [3.19]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a Thienopyridine P2Y12 ADP-Receptor Antagonist (Prodrug Antiplatelet).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Essential Medicines.
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.19], p. 30): Plavix (Sanofi), Deplatt (Torrent), Clopilet (Sun Pharma), Clopitab (Lupin), Ceruvin (Ranbaxy/Sun), Clavix (Intas) — Strengths & Forms: Oral Film-Coated Tablets: 75 mg, 150 mg, 300 mg (loading)
Oral Film-Coated Tablets: 75 mg, 150 mg, 300 mg (loading)
3. Mechanism of Action & Pharmacodynamics
Complementary dual irreversible blockade of platelet activation pathways for the entire 7–10 day lifespan of the anucleate platelet: (1) Low-dose Aspirin (75–150 mg) selectively and irreversibly acetylates Serine-529 of platelet Cyclooxygenase-1 (COX-1) in the portal circulation, abolishing Thromboxane A2 (TXA2) synthesis while sparing endothelial PGI2 synthesis; (2) Clopidogrel (an inactive thienopyridine prodrug converted via two-step hepatic CYP2C19 oxidation to its active thiol metabolite) forms an irreversible covalent disulfide bond with Cysteine residues on the platelet P2Y12 ADP receptor, preventing Gi-mediated inhibition of Adenylyl Cyclase and blocking GPIIb/IIIa fibrinogen receptor activation.
4. Therapeutic Indications & Evidence-Supported Uses
- Acute Coronary Syndrome (STEMI, NSTEMI, Unstable Angina) and post-Percutaneous Coronary Intervention (PCI) to prevent stent thrombosis
- Secondary prevention of atherothrombotic ischaemic stroke and peripheral arterial disease
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: ACS Loading Dose: Clopidogrel 300–600 mg + Chewable Uncoated Aspirin 150–325 mg stat. Maintenance DAPT: Clopidogrel 75 mg + Enteric-Coated Aspirin 75 mg orally once daily after food.
Administration & Meal Timing: Oral; take once daily with food.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Avoid in severe hepatic impairment with coagulopathy or bleeding diathesis.
Use caution in severe renal impairment (uraemic platelet dysfunction increases bleeding risk).
Avoid in severe hepatic impairment with coagulopathy or bleeding diathesis.
7. Contraindications, Precautions & High-Risk Warnings
- Active pathological bleeding (peptic ulcer haemorrhage or intracranial haemorrhage)
- Children/adolescents with viral febrile illness (Aspirin precipitates Reye's syndrome — acute encephalopathy + microvesicular fatty liver)
Key Clinical Precautions: Avoid in severe hepatic impairment with coagulopathy or bleeding diathesis.
8. Adverse Effects Profile
- Gastrointestinal haemorrhage, epistaxis, ecchymosis, and intracranial bleeding
- Stent thrombosis if DAPT is discontinued prematurely within 6–12 months after drug-eluting coronary stent placement
- Aspirin-exacerbated respiratory disease (bronchospasm via leukotriene shunting) and rare TTP (Thrombotic Thrombocytopenic Purpura with Clopidogrel)
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Omeprazole & Esomeprazole: potently inhibit CYP2C19 and reduce conversion of Clopidogrel prodrug to its active thiol metabolite by 40%–45% — ALWAYS use Pantoprazole or Rabeprazole when GI gastroprotection is needed with Clopidogrel!
- NSAIDs (Ibuprofen, Naproxen): compete with Aspirin for access to the COX-1 Serine-529 channel ( cancelling Aspirin's cardioprotection) and multiply GI bleed risk
- Oral Anticoagulants (Warfarin, Rivaroxaban, Dabigatran) & SSRIs: major additive bleeding risk
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- NEVER stop Clopidogrel or Aspirin after coronary stent placement without consulting your cardiologist, as stopping early can cause sudden fatal stent clotting.
- If you need an acid-reducer for stomach protection, use Pantoprazole (avoid Omeprazole/Esomeprazole as they block Clopidogrel activation).
- For elective major surgery, Clopidogrel typically requires a 5-day washout (7 days for Prasugrel, 3–5 days for Ticagrelor) — coordinate with your cardiologist and surgeon.
Storage, Stability & Dispensing Safeguards: Store below 25–30°C protected from moisture (Aspirin hydrolyses in humidity to salicylic + acetic acid with a vinegar odour).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.